FUTURA MEDICAL PLC - Full year results for the year ended 31 December 2025

Futura Medical PLC’s latest investor update highlights a transitional year marked by strategic reset, challenging financial results, and a renewed growth strategy focused on its sexual health portfolio. Full-year 2025 revenue declined to £1.7 million, reflecting a shift from milestone-driven income to demand-led sales, while gross margins remained strong at 73%. The company reported an underlying operating loss of £4.5 million, alongside disciplined cost control, improved capital allocation, and a strengthened balance sheet following a £2.7 million fundraise. Commercial performance of its flagship product, Eroxon, fell short of expectations due to positioning and usage challenges, prompting a refined go-to-market strategy targeting defined consumer segments and improved partner collaboration. Looking ahead, the growth strategy centers on driving revenue recovery, expanding margins, and accelerating product innovation, including Eroxon Intense (targeted 2027 launch) and the WSD4000 female sexual health platform (targeted 2028 launch), both supported by positive clinical and consumer data. With a robust product pipeline, active funding initiatives, and multiple 2026 value inflection points—including regulatory milestones and partnership expansion—the company aims to enhance long-term shareholder value while advancing toward sustainable revenue growth and improved operational performance.